Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05116579 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)

Name: Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi) — clinical trial record (NCT05116579)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusUnknown

PhaseNot specified

SponsorSun Yat-sen University

Started2021-10-31

View on ClinicalTrials.gov ↗

Amendment history

2026-09-06

Trial status changed: Recruiting → Unknown

2024-08-31

Study Status, Eligibility v1

Trial statusRecruiting→Unknown

Completion date2023-08-31→2025-08-31

Eligibility criteria+39 characters

[...] cytologically confirmed adenocarcinoma of the prostate with Homologous Recombination Deficiency or DDR genes mutation (BRCA1/2, ATM, BARD1, BRIP1, CDK12, CHEK [...]

2021-11-01

Original filing

Sun Yat-sen University

609 trials monitored

See 13 trials at risk

Prostate Cancer

2,471 trials monitored

See 156 trials at risk

To evaluate the application value of customized ctDNA monitoring in efficacy assessment and prediction during PARPi treatment

Trial Details

NCT Number	NCT05116579
Lead Sponsor	Sun Yat-sen University
Conditions	Metastatic Castration-resistant Prostate Cancer
Enrollment	30 participants
Start Date	2021-10-31
Primary Completion	2023-03-31 (estimated)
Study Completion	2025-08-31 (estimated)
Updated on ClinicalTrials.gov	2024-09-05